Psoriasis and psychiatric morbidity: a profile from a tertiary care centre of Eastern India

Sarkar, Sonali; Sarkar, Arnab; Saha, Revanta; Sarkar, Tanusree

doi:10.4103/2249-4863.130267

Cited by 12 publications

(12 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 3 41 ] The effect of psychiatric morbidity on severity of psoriasis has also been studied individually. [ 4 5 6 7 ] None of the studies reviewed here have compared the quality of life and PASI scores in patients with and without psychiatric morbidity. We have tried to investigate the effect of depression/anxiety on quality of life and severity of psoriasis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Cross-sectional Study of Prevalence and Implications of Depression and Anxiety in Psoriasis

Lakshmy¹,

Balasundaram²,

Sarkar³

et al. 2015

Indian Journal of Psychological Medicine

View full text Add to dashboard Cite

Background:Physical and mental comorbidity is common and has significant implications for overall health outcomes. Psoriasis, a psychocutaneous disorder, is a classic example of mental-physical comorbidity.Aims:In view of the impact of socio-cultural influences on mind-body interactions and the paucity of Indian research pertaining to psychiatric morbidity in psoriatic patients, this study was undertaken to measure the prevalence of anxiety and depression in patients with psoriasis, and to correlate these with severity of psoriasis and quality of life.Materials and Methods:This cross-sectional study was conducted on 90 consecutive patients of psoriasis, over a period of 12 months, in a tertiary care centre. The Psoriasis Area and Severity Index was used to assess severity of psoriasis. PHQ-9, GAD-7 and the Perceived Stress Scale were used to screen for depression, anxiety and perceived stress respectively. The WHOQOL-BREF was used to determine the quality of life.Statistics Analysis:All analysis was performed using Microsoft Excel software and Statistical Package for Social Sciences.Results:A total of 71 (78.9%) subjects had depression and 69 (76.7%) had anxiety. Fifty one patients had significant stress. A significant positive correlation was established between psoriasis variables (severity and duration of psoriasis) and psychological variables (depression, anxiety and stress). Severity of psoriasis had a significant negative correlation with social relationships and environmental domains of WHOQOL. Quality of life was significantly worse in patients with psoriasis with comorbid anxiety/depression.Conclusion:Patients with psoriasis have a clinically significant prevalence of depression, anxiety and perceived stress. This study highlights the complex relationship between psoriasis, psychiatric comorbidity and quality of life and the need to simultaneously consider dermatological and psychological factors.

show abstract

Section: Discussionmentioning

confidence: 99%

“…[ 3 ] Many studies done worldwide have shown that psychiatric comorbidities are frequently found among patients with psoriasis. [ 4 5 6 7 8 ] In view of the paucity of Indian research pertaining to the psychological aspects of psoriasis; it is necessary for further research to be conducted specifically in our cultural milieu.…”

Section: Introductionmentioning

confidence: 99%

A Cross-sectional Study of Prevalence and Implications of Depression and Anxiety in Psoriasis

Lakshmy¹,

Balasundaram²,

Sarkar³

et al. 2015

Indian Journal of Psychological Medicine

View full text Add to dashboard Cite

show abstract

“…5 Psoriasis is a chronic inflammatory disorder that has a major impact on socioeconomic aspects of a patient's life. 26 It can produce psychological stress, embarrassment, disgrace, and physical discomfort. 27 Patients with psoriasis have a high risk of depression, anxiety, and may develop suicidal tendencies.…”

Section: Psoriasis: "The Traumatizing Aspects"mentioning

confidence: 99%

“…The skin diseases can result in considerable psychological distress, an important clinical feature of many cutaneous diseases . Psoriasis is a chronic inflammatory disorder that has a major impact on socioeconomic aspects of a patient's life . It can produce psychological stress, embarrassment, disgrace, and physical discomfort .…”

Section: Introduction To Psoriasismentioning

confidence: 99%

Psoriasis: implication to disease and therapeutic strategies, with an emphasis on drug delivery approaches

Todke

Shah

2018

Int J Dermatology

View full text Add to dashboard Cite

Skin is the most visible and vulnerable organ of the integumentary system. Psoriasis is a chronic inflammatory skin disorder with an equal prevalence rate in males and females globally. Psoriasis is seen today beyond a cosmetic turmoil as it significantly impacts the socioeconomic life of the patients. Patients with severe psoriasis report feeling denounced and isolated. Despite detailed understanding of the molecular mechanisms and pathogenesis of psoriasis, issues like the autoimmune cause of inflammation and role of external, genetic, cutaneous, and systemic factors on initiation, progression, and treatment of psoriasis are still ambiguous. The present review summarizes immunogenic pathophysiology of psoriasis with a cascade of events from stimuli-based release of self-nucleotides to the hyperproliferation of keratinocytes leading to psoriasis. The review emphasizes challenges and hurdles toward the efficient treatment of psoriasis. The review also provides a detailed understanding of conventional and novel treatment strategies including drug delivery approaches and patented technologies for therapeutic and preventive approaches leading to improved outcome for psoriasis patients. The review summarizes a brief insight on biologics and gene therapy that has resulted in a paradigm shift in the treatment strategies for psoriasis management.

show abstract

“…It affects 1.4%–2.0% of the population and comprises 2.6% of skin-related visits to primary care physicians or between 0.3% and 0.6% of all visits to family physicians. [1] In India, the prevalence of psoriasis varies from 0.44% to 2.8%, it is twice more common in males compared to females, and most of the patients are in their third or fourth decade at the time of presentation. [2]…”

Section: Introductionmentioning

confidence: 99%

Secukinumab – first in class interleukin-17A inhibitor for the treatment of psoriasis

Godse

2017

Indian J Dermatol

View full text Add to dashboard Cite

Psoriasis is a complex inflammatory disease that occurs in genetically susceptible individuals and presents with the development of erythematous scaly plaques on the skin. Interleukins (ILs) in the Th17 pathway play a pivotal role in the pathogenesis of psoriasis and have thus become targets for recent biologic drug development. Secukinumab is a human monoclonal IgG1k antibody that has been developed to target and block the actions of IL-17A. Secukinumab recently approved for use as first-line systemic therapy in a patient with moderate to severe psoriasis has been studied first in psoriasis before other diseases. Both Phase II and III clinical trials have demonstrated the effectiveness of secukinumab in the treatment of moderate-to-severe plaque psoriasis, and it has demonstrated superiority to other comparable biologics on the market, including the tumor necrosis factor inhibitor etanercept. Secukinumab has also shown superiority to ustekinumab, a relatively recent biologic introduced for the treatment of psoriasis. Besides demonstrating better efficacy compared to etanercept and ustekinumab, secukinumab has also demonstrated a greater impact of the quality of life of patients with a comparable safety profile. Secukinumab shows great promise in having a tremendous impact on the treatment of plaque psoriasis based on its ability to produce similar, if not better, clinical outcomes than other biologic antipsoriasis medications.

show abstract

Psoriasis and psychiatric morbidity: a profile from a tertiary care centre of Eastern India

Cited by 12 publications

References 11 publications

A Cross-sectional Study of Prevalence and Implications of Depression and Anxiety in Psoriasis

A Cross-sectional Study of Prevalence and Implications of Depression and Anxiety in Psoriasis

Psoriasis: implication to disease and therapeutic strategies, with an emphasis on drug delivery approaches

Secukinumab – first in class interleukin-17A inhibitor for the treatment of psoriasis

Contact Info

Product

Resources

About